• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【药物名称】E-0712

【化学名称】4-(3,7,11,15-Tetramethyl-1-oxo-6,10,14-hexadecatrienyl)morpholine
      4-(3,7,11,15-Tetramethyl-6,10,14-hexadecatrienoyl)morpholine

【CA登记号】80016-56-4 (E,E-isomer)

【 分 子 式 】C24H41NO2

【 分 子 量 】375.59987

【开发单位】Eisai (Originator)

【药理作用】GASTROINTESTINAL DRUGS, Hepatoprotectants, Liver and Biliary Tract Disorders, Treatment of

合成路线1

The condensation of ethyl cyanoacetate (I) with farnesylacetone (II) by means of acetic acid ammonium acetate in refluxing benzene gives ethyl 2-cyano-3,7,11,15-tetramethyl-6,10,14-hexadecatrienoate (III), which is decarbo-xylated with NaOH in propylene glycol at room temperature yielding 3,7,11,15-tetramethyl-6,10,14-hexadecatrienonitrile (IV). The hydrolysis of (IV) with KOH in propylene glycol water at 130 C affords 3,7,11,15-tetramethyl-6,10,14-hexa-decatrienoic acid (V), which is finally condensed with morpholine (VI) by means of ethyl chlorocarbonate (VII) and triethylamine in THF.

1 Yamatsu, I.; et al. (Eisai Co., Ltd.); Polyprenylcarboxylic acid amides useful for treating liver dysfunction. BE 0884754; DE 3030462; FR 2463122; FR 2497802; GB 2058782; JP 8126852; JP 8132442; US 4456603 .
2 Serradell, M.N.; Castaner, J.; E-0712. Drugs Fut 1985, 10, 5, 387.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 29329 (5E,9E)-6,10,14-trimethyl-5,9,13-pentadecatrien-2-one 762-29-8 C18H30O 详情 详情
(II) 11877 Cyanoacetic acid ethyl ester; Ethyl 2-cyanoacetate; Ethyl cyanoacetate; Ethyl isocyanacetate 105-56-6 C5H7NO2 详情 详情
(III) 29330 ethyl (6E,10E)-2-cyano-3,7,11,15-tetramethyl-6,10,14-hexadecatrienoate C23H37NO2 详情 详情
(IV) 29331 (6E,10E)-3,7,11,15-tetramethyl-6,10,14-hexadecatrienenitrile C20H33N 详情 详情
(V) 29332 (6E,10E)-3,7,11,15-tetramethyl-6,10,14-hexadecatrienoic acid C20H34O2 详情 详情
(VI) 10388 Morpholine 110-91-8 C4H9NO 详情 详情
(VII) 11229 1-[(Chlorocarbonyl)oxy]ethane;ethyl carbonochloridate; Carbonchloridic acid ethyl ester;Ethyl chloroformate;Ethyl chlorocarbonate 541-41-3 C3H5ClO2 详情 详情
Extended Information